Warning on Compounded GLP-1s; Ketoacidosis Deaths; Axon Stim for Diabetic Nerve Pain

The Obesity Society, Obesity Action Coalition, and Obesity Medicine Association released a joint statement warning against the use of compounded GLP-1 receptor agonists.

Novo Nordisk resumed shipments of its 1.7-mg dose of semaglutide (Wegovy), which has been in short supply since mid-December, the company said. (Reuters)

From 1999 to 2019, death from diabetic ketoacidosis and hyperosmolar hyperglycemic state increased, with the biggest jumps seen in adults 65 and older. (JAMA)

Neuralace Medical announced FDA clearance of Axon Therapy noninvasive peripheral nerve stimulation for chronic painful diabetic neuropathy.

A study of electronic health records found an association between testosterone replacement therapy and increased risk of cardiovascular disease in men with hypogonadism — a contrast to the results from the randomized TRAVERSE trial that cleared testosterone therapy of major adverse cardiac event risk. (Epic Research)

Meanwhile, hormone replacement therapy in women and the duration of its use were both linked with a higher risk of rheumatoid arthritis. (RMD Open)

Endocrine-disrupting chemicals in plastics cost the U.S. roughly $250 billion in increased healthcare costs in 2018, researchers estimated in the Journal of the Endocrine Society.

Arsenic exposure — another diabetes precursor? A mouse study suggested so. (Environmental Health Perspectives)

Regardless of BMI and other comorbidities, Hispanic and Latino adults with a higher waist-to-hip ratio had a significantly higher risk for death. (JAMA Network Open)

Please enable JavaScript to view the

comments powered by Disqus.